Procter & Gamble Health Ltd on Wednesday reported its June quarter earnings with a profit decline of 43.7 per cent at Rs 16.78 crore in comparison to Rs 29.82 crore during the corresponding quarter of previous financial year. It posted revenue from operations at Rs 283.88 crore, down 5.7 per cent as against Rs 301.18 crore during the same period of FY24. The company EBITDA stood at Rs 48.3 crore, up 6.4 per cent YoY.
The company board also recommended a final dividend of Rs 60 per equity share, for the financial year ending June 30, 2024. “Considering the interim dividend of Rs 200 per share (including the one-time special dividend of Rs 150 per share), the total dividend payout for the fiscal will be Rs 260 per share, subject to the approval of the final dividend by shareholders of the company at the ensuing 57thAnnual General Meeting,” the company said in a regulatory filing.
During the quarter, the company reported sales at Rs 277 crore, down 5 per cent vs the previous year, owing to changes in the go-to-market model. The exceptional items include impairment charges amounting to Rs 20 crore, it said. For the full fiscal year ended June 30, 2024, the company recorded sales of Rs 1129 crore, down 6 per cent YoY.
Voltas posts Q1 profit growth by 158.5% YoY at Rs 334.23 crore, records 1 million AC sales
Trent posts Q1 profit jump of 134.7% at Rs 391.21 crore, revenue up 56.2% YoY, beats estimates
Maggi maker Nestle India posts Q1 profit growth of 6.9% YoY at Rs 746.60 crore despite external challenges, misses estimates
L&T Q1 Results: Profit rises by 11.7% at Rs 2785.72 crore, order book stood at Rs 70,936 crore
Milind Thatte, Managing Director, P&G Health India, said, “Our results this quarter reflect the typically seasonality of shipments during this period. In addition, we’ve made choices to strengthen the execution of our integrated strategy with the deployment of a transformed go-to-market model. We’re confident these changes will deliver superior reach, distribution, retail execution and improve our long-term competitiveness. Our strategy remains anchored on a focused product portfolio where performance is a key driver of brand preference, superiority (across product performance, packaging, brand communication, retail execution and value), constructive disruption and an agile, accountable organization. This integrated strategy continues to guide our efforts to generate sustainable, balanced top- and bottom-line growth and value creation.”
“We continue to navigate the evolving market dynamics with resilience and explore innovative solutions to ensure our trusted, quality brands remain the preferred choice for healthcare professionals and consumers alike,” he added.
From: financialexpress
Financial News
